Provided by Tiger Fintech (Singapore) Pte. Ltd.

JUNSHI BIO

15.060
+0.4603.15%
Volume:2.02M
Turnover:30.30M
Market Cap:14.84B
PE:-6.05
High:15.240
Open:14.780
Low:14.780
Close:14.600
Loading ...

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Surges 37% Yet Its Low P/S Is No Reason For Excitement

Simply Wall St.
·
03 Mar

Junshi Biosciences' 2024 Loss Narrows

MT Newswires Live
·
28 Feb

Shanghai Junshi Biosciences Malignant Tumpr Drug Gets NMPA's Nod for Clinical Trial

MT Newswires Live
·
06 Feb

Shanghai Junshi Biosciences Gets Clinical Trial Approval for Anti-tumor Drug; Shares Up 3%

MT Newswires Live
·
06 Feb

BRIEF-Shanghai Junshi Biosciences Gets Approval For Clinical Trial Of AWT020 Sterile Powder

Reuters
·
05 Feb

Shanghai Junshi Biosciences - Got Notice of Approval for Clinical Trial Awt020 Sterile Powder for Injection by Nmpa

THOMSON REUTERS
·
05 Feb

Shanghai Junshi Biosciences Enters Contract for Cancer Drug Distribution in Europe

MT Newswires Live
·
21 Jan

Shanghai Junshi Biosciences - Entering Into Distribution and Marketing Agreement With Leo Pharma

THOMSON REUTERS
·
20 Jan

Junshi Biosciences Gets Nod to Market Toripalimab in Australia

MT Newswires Live
·
20 Jan

Shanghai Junshi Biosciences Forecasts Slimmer Loss in 2024

MT Newswires Live
·
20 Jan

BRIEF-Junshi Biosciences Announces Toripalimab's Approval In Australia

Reuters
·
17 Jan

Junshi Biosciences Announces Toripalimab’s Approval in Australia

THOMSON REUTERS
·
17 Jan

Shanghai Junshi Biosciences Unit Gets China's Regular Approval for COVID-19 Treatment

MT Newswires Live
·
13 Jan

BRIEF-Shanghai Junshi Biosciences Receives Regular Approval Of Deuremidevir Hydrobromide Tablets By Nmpa

Reuters
·
10 Jan

Shanghai Junshi Biosciences - Regular Approval of Deuremidevir Hydrobromide Tablets by Nmpa

THOMSON REUTERS
·
10 Jan

Shanghai Junshi Biosciences' Investigational NDA for Tumor Drug Gets China Nod

MT Newswires Live
·
09 Jan